Decreased oral absorption of cyclosporine a after liver ischemia-reperfusion injury in rats: The contribution of CYP3A and p-glycoprotein to the first-pass metabolism in intestinal epithelial cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 249-255

  Ikemura, Kenji ^a   Urano, Kimihiko ^d   Matsuda, Hiroko ^a   Mizutani, Hideki ^c   Iwamoto, Takuya ^b   Okuda, Masahiro ^b  

^a MIE UNIVERSITY   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c KINJO GAKUIN UNIVERSITY   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; GLYCOPROTEIN P; KETOCONAZOLE; VILLIN; CYCLOSPORIN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FIRST PASS EFFECT; INTESTINE EPITHELIUM CELL; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SMALL INTESTINE; ANIMAL; BILE; BIOAVAILABILITY; HYDROXYLATION; INTESTINE ABSORPTION; INTESTINE MUCOSA; LIVER CIRCULATION; LIVER MICROSOME; METABOLISM; MICROSOME; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SECRETION; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; BILE; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; HYDROXYLATION; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, SMALL; KETOCONAZOLE; LIVER CIRCULATION; LIVER TRANSPLANTATION; MALE; MICROSOMES; MICROSOMES, LIVER; P-GLYCOPROTEIN; POSTOPERATIVE COMPLICATIONS; RATS; RATS, WISTAR; REPERFUSION INJURY; TESTOSTERONE;

EID: 59149099097     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145581     Document Type: Article

References (37)

1. Accatino L, Pizarro M, Solís N, Arrese M, and Koenig CS (2003) Bile secretory function after warm hepatic ischemia-reperfusion injury in the rat. Liver Transpl 9:1199-1210.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Cummins CL, Salphati L, Reid MJ, and Benet LZ (2003) In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 305:306-314.
4. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
5. Frangogiannis NG (2007) Chemokines in ischemia and reperfusion. Thromb Haemost 97:738-747.
6. Galaris D, Barbouti A, and Korantzopoulos P (2006) Oxidative stress in hepatic ischemia-reperfusion injury: the role of antioxidants and iron chelating compounds. Curr Pharm Des 12:2875-2890.
7. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471-478.
8. Hebert MF (1997) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27:201-214.
9. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
10. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
11. Izuishi K, Wakabayashi H, Maeba T, Ryu M, and Maeta H (2000) Lidocaine-metabolizing activity after warm ischemia and reperfusion of the rat liver in vivo. World J Surg 24:49-52.
12. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, and Miyamoto K (2006) Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol 72:1042-1050.
13. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, Stuart F, Meier-Kriesche HU, and Fryer J (1999) Low bioavailability of cyclosporine micro-emulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 67:333-335.
14. Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, and Reding R (2004) Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 364:1054-1061.
15. Lindholm A, Henricsson S, and Dahlqvist R (1990) The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 29:541-548.
16. Makhey VD, Guo A, Norris DA, Hu P, Yan J, and Sinko PJ (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160-1167.
17. Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, Tanaka K, and Inui K (2003) Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl 9:1108-1113.
18. Masuda S, Goto M, Okuda M, Ogura Y, Oike F, Kiuchi T, Tanaka K, and Inui K (2005) Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc 37:1728-1729.
19. Masuda S and Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184-198.
20. Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Delamos B, Stachak S, Van Thiel DH, Iwatsuki S, and Starzl TE (1988) Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 25:579-584.
21. Mohri K and Uesawa Y (2001) Enzymatic activities in the microsomes prepared from rat small intestinal epithelial cells by differential procedures. Pharm Res 18:1232-1236.
22. Nishio N, Katsura T, Ashida K, Okuda M, and Inui K (2005) Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab Dispos 33:1584-1587.
23. Omae T, Goto M, Shimomura M, Masuda S, Ito K, Okuda M, and Inui K (2005) Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. Biochem Pharmacol 69:561-568.
24. Pacher P and Gao B (2008) Endocannabinoids and liver disease: III. Endocannabi-noid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol 294:G850-G854.
25. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
26. Ptachcinski RJ, Venkataramanan R, and Burckart GJ (1986) Clinical pharmacoki-netics of cyclosporin. Clin Pharmacokinet 11:107-132.
27. Purdon MP and Lehman-McKeeman LD (1997) Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytes-tosterone metabolites. J Pharmacol Toxicol Methods 37:67-73.
28. Shimomura M, Masuda S, Saito H, Sakamoto S, Uemoto S, Tanaka K, and Inui K (2002) Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res 103:215-222.
29. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
30. Takemoto K, Yamazaki H, Tanaka Y, Nakajima M, and Yokoi T (2003) Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xeno-biotica 33:43-55.
31. Tanaka Y, Chen C, Maher JM, and Klaassen CD (2006) Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation 82:258-266.
32. Terrell AR, Daly TM, Hock KG, Kilgore DC, Wei TQ, Hernandez S, Weibe D, Fields L, Shaw LM, and Scott MG (2002) Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. Clin Chem 48:1059-1065.
33. Wandel C, Kim RB, Guengerich FP, and Wood AJ (2000) Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 28:895-898.
34. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
35. Wong S, Wong HT, and Wacher VJ (2002) Minimal effect of ketoconazole on cyclo-sporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence ofa significant vehicle effect on SangCyA absorption. Biopharm DrugDispos 23:53-57.
36. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
37. Zhang Y, Hsieh Y, Izumi T, Lin ET, and Benet LZ (1998) Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246-252.